Servier links with academia for diabetes and fatty liver disease research

French privately-held drugmaker Servier has updated on its collaboration with US Harvard University researcher, and will now explore a new avenue for treatments of type 2 diabetes and non-alcoholic fatty liver disease (NADLD).

Servier and Harvard researchers will embark on a three-year preclinical research project where the ultimate objective is to develop therapeutics targeting the microbiota for the treatment of type 2 diabetes and NAFLD. The work will be conducted by a multidisciplinary team of researchers from both parties.

Servier and Harvard researchers will embark on a three-year preclinical research project where the ultimate objective is to develop therapeutics targeting the microbiota for the treatment of type 2 diabetes and NAFLD. The collaboration combines the expertise of Servier researchers in the field of metabolism and drug development with the expertise of Emily Balskus, Professor of Chemistry and Chemical Biology in chemical discovery relating to the gut microbiome. Together, the parties hope to make important advances in understanding disease biology and to use emerging technologies to develop new treatment options for diseases with high unmet medical need.